Zalvac AB is founded around the research of Birgitta Henriques Normark and Staffan Normark. Their research explores the role of membrane vesicles - small nanosized particles released by bacteria - in the immune response.

By harnessing these vesicles, their work aims to create effective vaccines that give protection against different bacterial infections.

This innovative approach exploits the ability of vesicles to present antigens, providing a novel method for vaccine development that could lead to more effective vaccines eliciting broad protection against challenging infectious diseases.